Background: SWENOTECA has since 1998 offered patients with clinical stage I (CS I) nonseminoma, adjuvant chemotherapy with one course of bleomycin, etoposide and cisplatin (BEP). The aim has been to reduce the risk of relapse, sparing patients the need of toxic salvage treatment. Initial results on 312 patients treated with one course of adjuvant BEP, with a median follow-up of 4.5 years, have been previously published. We now report mature and expanded results. Results: At a median follow-up of 7.9 years, 12 relapses have occurred, all with IGCCC good prognosis. The latest relapse occurred 3.3 years after adjuvant treatment. The relapse rate at 5 years was 3.2% for patients with LVI and 1.6% for patients without LVI. Five-year cause-specific survival was 100%.
introduction
The Swedish and Norwegian Testicular Cancer Group (SWENOTECA) has developed management protocols and initiated studies for patients with testicular cancer since 1981. All hospitals treating testicular cancer in Norway and Sweden participate, accruing 600 patients annually. Currently, 42% of patients with testicular cancer are diagnosed with nonseminoma and 60% of these present in clinical stage I (CS I) [1] . The treatment of CS I nonseminoma has long been controversial. Since the introduction of cisplatin-based chemotherapy retroperitoneal lymph node dissection (RPLND), adjuvant chemotherapy (ACT) and active surveillance have been acceptable treatment options with excellent cause-specific survival rates. However, acute and potential morbidity and toxicities differ [2] , and different follow-up schedules are required.
The most robust prognostic factor for occult metastatic disease in CS I nonseminoma is the presence of lymphovascular invasion (LVI) in the primary tumor. From recent large and unselected patient series, we know that the risk of relapse following surveillance without ACT in patients with and without LVI is 50% and 15%, respectively [3] [4] [5] . Two courses of ACT with bleomycin, etoposide and cisplatin (BEP) effectively prevent risk of relapse [6] [7] [8] [9] , and is an established treatment option in patients with LVI. On the other hand, RPLND is decreasingly used in CS I nonseminoma and has been omitted as a standard treatment option in most guidelines [10] [11] [12] [13] [14] .
However, the difference in treatment burden between two courses of BEP as ACT and the three courses of BEP, which are sufficient in the majority of patients who relapse while on surveillance, is by many considered to be too small to justify unnecessary ACT in 50% of CS I patients. SWENOTECA initiated a prospective study in 1995 in which CS I nonseminoma patients without LVI were treated with one course of adjuvant cisplatin, vinblastine and bleomycin (CVB) and patients with LVI were treated with two courses of CVB. The results were disappointing, with an unexpected high level of toxicity and low efficacy [15] , and as a consequence SWENOTECA changed the adjuvant treatment to one course of BEP in 1998. Preliminary results were published in 2009 [7] . With a median follow-up of 4.5 years promising low relapse rates irrespective of LVI status were found. Since then, the study population has been expanded, and we now present long-term results of this prospective population-based study of ACT with one course of BEP in patients with CS I nonseminoma.
patients and methods
Between 31 May 1998 and 2 December 2010, a total of 517 Swedish and Norwegian men with CSI nonseminoma were treated with one course of adjuvant BEP. All were included in a prospective, community-based, multicenter SWENOTECA management program. CSI was confirmed by a second staging 6-8 weeks following orchiectomy. The clinical staging procedure consisted of clinical examination, CT of chest, abdomen and pelvis. The serum tumor markers β-human chorionic gonadotropin, α-fetoprotein and lactate dehydrogenase were assessed before, directly after orchiectomy and thence weekly until normal values were reached. The Swedish and Norwegian medical ethical committees approved the management program.
adjuvant treatment
Administered chemotherapy was the BEP regimen consisting of cisplatin 20 mg/m 2 daily day 1-5, etoposide 100 mg/m 2 daily day 1-5, and bleomycin 30 mg daily days 1, 5 and 15. Prophylactic granulocyte colony-stimulating factor or antibiotics were not used. Therapy was given 6-10 weeks following orchiectomy.
Patients with LVI were recommended one course of adjuvant BEP whereas patients without LVI could choose between surveillance and one course of adjuvant BEP. All patients were informed, both in writing and orally, about possible pros and cons of the different treatment options.
treatment of relapse
In case of relapse, treatment with chemotherapy and/or surgery was given according to a current SWENOTECA protocol for metastatic disease [16] . In isolated tumor marker-negative relapses in the retroperitoneal lymph nodes, primary RPLND was recommended. Residual disease after chemotherapy was surgically removed. In patients with retroperitoneal relapse exceeding 2 cm (largest transversal diameter) before chemotherapy, postchemotherapy RPLND was recommended to all patients irrespective of size of residual tumor. Currently, postchemotherapy RPLND is only recommended in patients not in complete remission (CR), i.e. with residual disease exceeding 1 cm in largest transversal diameter.
follow-up
All patients were observed according to a standardized follow-up protocol. The protocol has, however, changed during the time-frame of the study, resulting in less frequent abdominal imaging during later years. Most patients have been followed according to the follow-up schedule earlier reported [7] . Due to the experimental nature of one course of adjuvant BEP, the earlier follow-up schedule recommended a minimum of 10 years follow-up. During the 10 years of follow-up, abdominal imaging was frequently carried out, between 12 and 14 times. Currently, the recommended SWENOTECA follow-up schedule for patients treated with one course of adjuvant BEP comprises 5 years of followup. Follow-up includes clinical examination with measurement of tumor markers every 6 months the first 3 years, then yearly until end of follow-up. Abdominal imaging and chest X-ray are scheduled once a year the first 3 years and at the 5-year checkup. Magnetic resonance imaging is now the recommended modality for abdominal imaging. Additionally, tumor markers are evaluated on an outpatient basis with 2-month interval the first year, and 3-month intervals the second year.
statistical analysis
Relapse rates were defined with date of orchiectomy as reference time. Patients without relapse were censored at last documented follow-up or original articles
Annals of Oncology death from other causes. Overall survival was defined from the date of orchiectomy until death from any cause; cancer-specific survival was defined from the date of orchiectomy until death from germ-cell tumor or treatment.
Patients without events were censored at the date survival was confirmed by the national population registries. Relapse rates and survival were estimated by Kaplan-Meier survival curves. Follow-up time extended from date of orchiectomy until date of last documented follow-up or death. Median follow-up times are reported as a descriptive measure for patients within the groups specified. Based on the results from risk-adapted treatment in the SWENOTECA program and results from large unselected patient series, we have estimated the burden of treatment using different treatment scenarios in patients with CSI nonseminoma. The approaches were either surveillance for all, one course of adjuvant BEP for all, or a risk-adapted strategy with BEP × 1 for patients with LVI and surveillance for patients without LVI.
results
A total of 517 patients with CS I nonseminoma were given ACT with one BEP. The median age of patients was 29.5 years (range 15-71 years). The median follow-up was 7.9 years (range 0.2-14.2 years). Overall 76% of the patients have follow-up exceeding 5 years, and 30% with follow-up exceeding 10 years. Very few patients were lost to follow-up, and only 2.7% of patients have follow-up <2 years. Ten patients have died, one from progressive testicular cancer (Table 1) . This patient suffered multiple relapses and died at the age of 59, 7.8 years after orchiectomy. The 5-year overall-and cause-specific survival was 99.0% and 100%, respectively. The 10-year overall-and causespecific survival was 96.9% and 99.6%, respectively. Details regarding deceased patients are presented in Table 1 .
Of the 517 patients, 258 (50%) were diagnosed with LVI. In the remaining 259 patients, 255 (49%) were diagnosed without LVI and, in 4 patients, the pathologist concluded with uncertainty in regard to LVI status.
patients with LVI
In 258 patients with LVI, eight relapses occurred, resulting in a relapse rate of 3.2%; 95% confidence interval (CI) 1.6-6.4. Median time to relapse was 1.1 years (range 0.3-3.6 years) after orchiectomy (Table 2, Figure 1 ). All relapsing patients had retroperitoneal lymph node metastasis, with two patients also presenting with synchronous lymph nodes metastasis above the diaphragm. All relapses were good prognosis according to the IGCCC classification [17] . Seven relapsing patients received initial salvage chemotherapy with postchemotherapy RPLND.
One marker-negative patient was cured with primary RPLND alone. Another patient was cured for a second relapse occurring 1 year after completion of the first relapse treatment and had no evidence of disease 7 years after additional follow-up. One patient experienced several relapses and eventually died from metastatic testicular cancer (Table 3) .
patients without LVI
Of 255 patients without LVI, 4 were diagnosed with relapse, resulting in a relapse rate of 1.6%, 95% CI 0.6-4.2. (Table 2 , Figure 1 ). Median time to relapse was 1.2 years (range 0.9-1.8 years) after orchiectomy. All relapses occurred in the retroperitoneum only, with IGCCC good prognosis. Two patients were treated with primary RPLND only, whereas the remaining two patients were treated initially with salvage chemotherapy followed by postchemotherapy RPLND. No patient without LVI died from testicular cancer ( Table 2) .
diagnosis of relapse
Nine of 12 relapsing patients had negative markers at relapse, and all nine marker-negative relapses were detected by abdominal imaging. Three patients had elevated tumor markers at relapse, one in combination with finding on abdominal K-M RR, relapse rate, estimated using Kaplan-Meier survival curves; OS, overall survival estimated using Kaplan-Meier survival curves; CSS, causespecific survival estimated using Kaplan-Meier survival curves; LVI, lymphovascular invasion.
Time ( imaging, one with elevated tumor markers as the only sign of relapse and the last patient experienced abdominal pain in addition to having elevated tumor markers. All relapsing patients are in CR, except one who died of testicular cancer (Table 3) . The median follow-up since relapse in living patients is 8.7 years (range 2.9-11.8 years).
discussion
To our knowledge, this is the largest study on adjuvant treatment in CS I nonseminoma and provide mature long-term data on the use of one course of adjuvant BEP. The results confirm our previous findings of a low relapse rate and excellent survival. In accordance with previous studies on one course of adjuvant BEP, the long-term results of the present study do not indicate that relapse occurring after ACT tend to be refractory to salvage chemotherapy. Neither does ACT with one BEP seem to merely postpone relapse, and thus result in a 'late wave of metastasis' [18, 19] . A limitation of this study is the lack of randomization, however the population-based, prospective design of this study, should ensure a high external validity. One planned randomized study failed to accrue patients, and there are no planned randomized studies in this patient population. A prospective UK study in high-risk patients, NCT01726374 (111-Trial), have soon finished accrual and will give additional confirmation of the results of BEP × 1.
The rationale of ACT in CS I disease is to minimize the risk of late effects inflicted by the more extensive salvage treatment necessary to cure a relapse. Secondary cancers and cardiovascular disease constitute the most serious late effects, while other late and long-term effects include pulmonary toxicity, nephrotoxicity, neurotoxicity, ototoxicity, infertility, hypogonadism as well as several psychosocial sequelae [20] . So far, short ACT such as one adjuvant BEP does not seem to compromise long-term hypogonadism, neurotoxicity, fertility, paternity or cognition [18, [21] [22] [23] although data regarding secondary cancers and cardiovascular disease are still lacking. However, mounting evidence indicates the risk of late toxicity to increase with the burden of treatment [21, [24] [25] [26] .
One course of adjuvant BEP reduced the risk of relapse by 90%-95%, both in patients with and without LVI. In this study, patients with LVI constitute 50% of the treated patients, due to the fact that patients without LVI had a choice between surveillance or one course of adjuvant BEP. We know that patients with LVI represents about 33% of the total CS I nonseminoma population [7] .
Only 9 of 517 (1.7%) patients were treated with salvage chemotherapy. Although a RPLND was recommended treatment in marker-negative relapse in retroperitoneal lymph nodes, 2 such patients were given initially salvage chemotherapy. Both were found to have teratoma at postchemotherapy RPLND, and may not have needed chemotherapy. Accordingly, it is possible that only 7 of 517 (1.4%) patients actually required salvage chemotherapy. In a corresponding unselected population of CS I nonseminoma managed by surveillance, the expected number of patients requiring salvage therapy would have been 129 (25%).
Today, some groups recommend surveillance for all patients with CS I nonseminoma irrespective of risk factors such as LVI [27] . Undoubtedly, surveillance remains an acceptable option for patients without LVI, of which 85% are cured by orchiectomy alone. Overtreatment of patients with LVI is the obvious disadvantage of surveillance in patients with LVI as 50% will later require salvage chemotherapy compared with 2.3% following one course of adjuvant BEP. The treatment burden in these patients will comprise three to four courses of salvage chemotherapy, possibly followed by a postchemotherapy RPLND as well as other residual tumor resections. Additionally, the psychological distress from having a recurrence after primary surveillance is poorly studied. Table 4 presents a calculated overview of the expected burden of treatment following ACT with one BEP or surveillance in CS I nonseminoma. The calculation visualizes the massive reduction in patients exposed to salvage chemotherapy, particular in the group of patients with LVI. Although the gain is less in patients without LVI, one course of adjuvant BEP close to eliminates the risk of patients later being exposed to salvage chemotherapy. In patients without LVI, this must be balanced against the fact that 85% of patients will be cured by surveillance alone.
As one course of adjuvant BEP was experimental treatment, our patients were followed a minimum of 10 years. Although late relapses still may be possible, they are expected to be rare, and not more common than in patients on surveillance. No relapse later than 5 years were detected in this patient series with 75% of patients followed more than 5 years. Five years follow-up in CS I nonseminoma patients treated with one adjuvant BEP course seems to be sufficient. One course of adjuvant BEP should, together with surveillance, be considered a standard option in patients with CSI nonseminoma. One course of adjuvant BEP is recommended by SWENOTECA to patients with LVI. The evidence on safety and efficacy of one course of BEP now exceeds that of two courses of BEP and, in our opinion, two courses of adjuvant BEP represent overtreatment in this patient population.
Patients with CS I nonseminoma should be informed about the possibility of adjuvant treatment, and the possible extent of treatment following relapse after surveillance. As an option to active surveillance, SWENOTECA also offer patients without LVI one course of adjuvant BEP. A well-informed patient is mandatory, and patient autonomy must be pursued.
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